^
Association details:
| Biomarker: | TROP2 overexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Trodelvy (sacituzumab govitecan-hziy) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer
Published date:
10/27/2020
Excerpt:
...in mice bearing higher Trop-2-expressing C13 and C39 tumors after Trop-2 transfection, SG provided a significant survival benefit, even compared to irinotecan (MST = 97d vs. 35d for C13, and 81d vs. 28d for C39, respectively; P < 0.0007)….these data strongly support the hypothesis that as a biomarker, high surface Trop-2 expression on a patient’s tumor may be predictive of a positive clinical outcome for SG therapy.
DOI:
10.18632/oncotarget.27766
